Mizuho raised the firm's price target on BrightSpring Health to $52 from $50 and keeps an Outperform rating on the shares. The company's investor day brought an "attractive" mid-double-digit adjusted EBITDA intermediate growth algorithm, the analyst tells investors in a research note. The firm sees more upside potential than downside risk to its new estimates given BrightSpring's business diversification.
